-
Scholar Rock and SRK 015 – EXCITING NEW POTENTIAL TREATMENT FOR SMA
In this episode of the Morale Monologue, I’m discussing another biopharmaceutical company by the name of Scholar Rock, and their potential treatment known as SRK-015. I discuss how SRK-015 impacts our body, and how it differs from Spinraza, Zolgensma and risdiplam. While it may be over a year before this potential treatment gets approved by the FDA, it’s still proof that pharmaceutical companies are making advancements toward new treatments for those of us who suffer from spinal muscular atrophy.
- SRK-015 Data Continue to Support Potential for SMA, Scholar Rock Says: https://smanewstoday.com/2020/02/21/srk-015-data-continue-to-support-potential-for-sma-scholar-rock-says/
- Early Data Support SRK-015 Development for SMA Types 2–3, Scholar Rock Says: https://smanewstoday.com/2019/10/09/early-data-support-srk-015-development-for-sma-types-2-3-scholar-rock-says/
- Scholar Rock Announces Additional Preclinical Data Supporting SRK-015 as Potential SMA Treatment: https://smanewstoday.com/2018/11/30/additional-preclinical-data-supports-srk-015-as-potential-sma-treatment/
-
2 Replies
-
I do remember hearing about this one a while back. Thanks for the great info!
-
I’ve had my eye on this drug for a while. Thinking it’d be a good cocktail with Spinraza. Happy to see things moving in the right direction.
Log in to reply.